{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:15:59Z","timestamp":1784740559353,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40272-021-00490-y","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T01:02:20Z","timestamp":1647392540000},"page":"175-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to &lt;\u00a018 Years"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct02118766","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02118792","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Thomas A.","family":"Luger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9167-5729","authenticated-orcid":false,"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Zaenglein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Ports","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"issue":"2","key":"490_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","volume":"22","author":"T Bieber","year":"2010","unstructured":"Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125\u201337.","journal-title":"Ann Dermatol"},{"issue":"12","key":"490_CR2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/all.12049","volume":"67","author":"T Bieber","year":"2012","unstructured":"Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67(12):1475\u201382.","journal-title":"Allergy"},{"issue":"3","key":"490_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1525-1470.2005.22303.x","volume":"22","author":"CL Carroll","year":"2005","unstructured":"Carroll CL, Balkrishnan R, Feldman SR, Fleischer AB Jr, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"490_CR4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jaci.2015.09.011","volume":"136","author":"DY Leung","year":"2015","unstructured":"Leung DY. Atopic dermatitis: age and race do matter! J Allergy Clin Immunol. 2015;136(5):1265\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"490_CR5","doi-asserted-by":"publisher","first-page":"P2094","DOI":"10.1016\/j.jaci.2018.02.040","volume":"141","author":"PM Brunner","year":"2018","unstructured":"Brunner PM, Israel A, Zhang N, Leonard A, Wen HC, Huynh T, et al. Early-onset pediatric atopic dermatitis is characterized by TH2\/TH17\/TH22-centered inflammation and lipid alterations. J Allergy Clin Immunol. 2018;141(6):P2094\u2013106.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"490_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2500\/aap.2011.32.3462","volume":"32","author":"JS Chou","year":"2011","unstructured":"Chou JS, LeBovidge J, Timmons K, Elverson W, Morrill J, Schneider LC. Predictors of clinical success in a multidisciplinary model of atopic dermatitis treatment. Allergy Asthma Proc. 2011;32(5):377\u201383.","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"490_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"490_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/11319300-000000000-00000","volume":"12","author":"M Kalavala","year":"2011","unstructured":"Kalavala M, Dohil MA. Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence. Am J Clin Dermatol. 2011;12(1):15\u201324.","journal-title":"Am J Clin Dermatol"},{"key":"490_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12887-016-0607-9","volume":"16","author":"EC Siegfried","year":"2016","unstructured":"Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.","journal-title":"BMC Pediatr"},{"issue":"5","key":"490_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000484407","volume":"233","author":"U Nygaard","year":"2017","unstructured":"Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233(5):333\u201343.","journal-title":"Dermatology"},{"key":"490_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jpeds.2020.02.015","volume":"221","author":"AB Fishbein","year":"2020","unstructured":"Fishbein AB, Hamideh N, Lor J, Zhao S, Kruse L, Mason M, et al. Management of atopic dermatitis in children younger than two years of age by community pediatricians: a survey and chart review. J Pedriatr. 2020;221:138-44.e3.","journal-title":"J Pedriatr."},{"issue":"1","key":"490_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/1523-1747.ep12297888","volume":"107","author":"JM Hanifin","year":"1996","unstructured":"Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR Jr, Kirby DS, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107(1):51\u20136.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"490_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/1523-1747.ep12472344","volume":"100","author":"SC Chan","year":"1993","unstructured":"Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol. 1993;100(5):681\u20134.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"490_CR14","first-page":"390","volume":"15","author":"K Jarnagin","year":"2016","unstructured":"Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, Guttman-Yassky E, et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis. J Drugs Dermatol. 2016;15(4):390\u20136.","journal-title":"J Drugs Dermatol"},{"key":"490_CR15","unstructured":"Eucrisa. Prescribing information. Pfizer Inc. 2020. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=5331. Accessed 6 Oct 2021."},{"key":"490_CR16","unstructured":"Staquis.. Prescribing information. Pfizer Australia Pty Ltd. 2019. https:\/\/apps.medicines.org.au\/files\/pfcstaqo.pdf. Accessed 6 Oct 2021."},{"key":"490_CR17","unstructured":"Preeucrisa. Prescribing information. Pfizer Canada Inc.. 2018. https:\/\/www.pfizer.ca\/sites\/default\/files\/202107\/Vyndamax_PM_EN_240239_09-Jul-2021.pdf. Accessed 6 Oct 2021."},{"key":"490_CR18","unstructured":"Staquis.. Summary of product characteristics. Pfizer Europe. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/staquis. Accessed 6 Oct 2021."},{"key":"490_CR19","unstructured":"Staquis.. Prescribing information. Pfizer Pharmaceuticals Israel. 2019. https:\/\/data.health.gov.il\/drugs\/alonim\/Rishum_10_418411819.pdf. Accessed 6 Oct 2021."},{"key":"490_CR20","unstructured":"Staquis.. Prescribing information. Pfizer Inc. 2020. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=5331. Accessed 6 Oct 2021."},{"issue":"2","key":"490_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/pde.12780","volume":"33","author":"WL Tom","year":"2016","unstructured":"Tom WL, Van Syoc M, Chanda S, Zane LT. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study. Pediatr Dermatol. 2016;33(2):150\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"10","key":"490_CR22","first-page":"1108","volume":"14","author":"DF Murrell","year":"2015","unstructured":"Murrell DF, Gebauer K, Spelman L, Zane LT. Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol. 2015;14(10):1108\u201312.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"490_CR23","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jaci.2019.06.047","volume":"144","author":"R Bissonnette","year":"2019","unstructured":"Bissonnette R, Pavel AB, Diaz A, Werth JL, Zang C, Vranic I, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol. 2019;144(5):1274\u201389.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"490_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","volume":"21","author":"J Schlessinger","year":"2020","unstructured":"Schlessinger J, Shepard JS, Gower R, Su JC, Lynde C, Cha A, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol. 2020;21(2):275\u201384.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"490_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","volume":"75","author":"AS Paller","year":"2016","unstructured":"Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494\u2013503.e6.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"490_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","volume":"77","author":"LF Eichenfield","year":"2017","unstructured":"Eichenfield LF, Call RS, Forsha DW, Fowler J Jr, Hebert AA, Spellman M, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77(4):641\u20139.e5.","journal-title":"J Am Acad Dermatol"},{"key":"490_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/itx.0000000000000013","volume":"3","author":"G Yosipovitch","year":"2018","unstructured":"Yosipovitch G, Simpson EL, Bushmakin AG, Cappelleri JC, Luger T, St\u00e4nder S, et al. Assessment of pruritus in atopic dermatitis: validation of the Severity of Pruritus Scale (SPS). Itch. 2018;3:13.","journal-title":"Itch"},{"issue":"5","key":"490_CR28","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/bjd.15641","volume":"177","author":"R Chopra","year":"2017","unstructured":"Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316\u201321.","journal-title":"Br J Dermatol"},{"issue":"4","key":"490_CR29","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/pde.12872","volume":"33","author":"LT Zane","year":"2016","unstructured":"Zane LT, Kircik L, Call R, Tschen E, Draelos ZD, Chanda S, et al. Crisaborole topical ointment, 2% in patients 2 to 17 years of age with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure (MUSE) study. Pediatr Dermatol. 2016;33(4):380\u20137.","journal-title":"Pediatr Dermatol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00490-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-021-00490-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00490-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T21:52:25Z","timestamp":1700344345000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-021-00490-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1007\/s40272-021-00490-y","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"19 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thomas A. Luger has served as an investigator for Pfizer, AbbVie, Celgene, Eli Lilly, LEO Pharma, Menlo Therapeutics, Novartis, and Sandoz; served as a member of scientific advisory boards for Pfizer, AbbVie, Argenx, Celgene, Ceres Pharma, Galderma, Eli Lilly, Janssen-Cilag, La Roche-Posay, LEO Pharma, Menlo Therapeutics, Mylan\/Meda AB, Novartis, Pierre Fabre, Piqur Therapeutics, Sandoz, Sanofi-Aventis, and Symrise; and has received funding from Pfizer, AbbVie, Celgene, Janssen-Cilag, Merck Sharp & Dohme, Mylan\/Meda AB, Novartis, and Wolff Laboratories. Adelaide A. Hebert discloses that research funding was paid to UTHealth McGovern Medical School from Pfizer, Anacor, Arcutis, Cutanea, Brickell, Dermira, GlaxoSmithKline, and Novan. She has received honoraria as a member of data safety monitoring boards for Bausch, GlaxoSmithKline, and Regeneron-Sanofi and has received honoraria from Pfizer, Biofrontera, Cutanea, Dermavant, Dermira, Galderma, Eli Lilly, Leo Pharma, Ortho Dermatologics, Pierre Fabre, and Verrica. Andrea L. Zaenglein has served as an investigator for AbbVie, Arcutis, Dermavant, Incyte, and Pfizer and as a consultant for Cassiopea and Verrica. Jonathan I. Silverberg has served as an investigator for Celgene, Eli Lilly, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, and Regeneron-Sanofi; as a consultant for Pfizer, AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermira, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron, and Sanofi; and as a speaker for Regeneron and Sanofi. Huaming Tan and Michael A. Zielinski are employees of and stockholders in Pfizer Inc. William C. Ports was an employee of and stockholder in Pfizer Inc. at the time of this analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Upon request and subject to certain criteria, conditions and exceptions (see https:\/\/www.pfizer.com\/science\/clinical-trials\/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the USA and\/or EU or (2) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study was approved by the local medical ethical committee, and all data were processed anonymously, according to privacy legislation. All parent(s)\/legal guardian(s) provided written informed consent. This study was conducted in compliance with ethical principles originating in the Declaration of Helsinki and in compliance with the International Committee on Harmonisation and Good Clinical Practice Guidelines.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All parent(s) or legal guardian(s) provided written informed consent.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Thomas A. Luger, Adelaide A. Hebert, Andrea L. Zaenglein, Jonathan I. Silverberg, William C. Ports, and Michael A. Zielinski contributed to the conception and design of the analysis, the interpretation of the data, and the drafting and revision of the manuscript. Huaming Tan carried out the analysis and contributed to the interpretation of the data and the drafting and revision of the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}